ArticleFrontiers in surgery2025
Endoscopic discectomy for L4-L5 disc herniation: percutaneous endoscopic transforaminal discectomy vs. unilateral biportal endoscopic discectomy.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Efficacy and safety of unilateral biportal endoscopy versus Percutaneous endoscopic foraminal discectomy in the treatment of lumbar disc herniation: a systematic review and meta-analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Review
- Comparison of outcomes between unilateral biportal endoscopic discectomy and percutaneous transforaminal endoscopic discectomy in single-level lumbar disc herniation.Frontiers in surgery · 2026Article
- Intraspinal versus Extraspinal Acupotomy Decompression, or Their Combination, for Lumbar Disc Herniation: Protocol for a Three-Arm, Randomized, Single-Blind Controlled Trial.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study design: Retrospective evaluation. Objective: This study aims to compare the clinical outcomes of percutaneous endoscopic transforaminal discectomy (PETD) and unilateral biportal endoscopic discectomy (UBED) in the management of L4-L5 disc herniation, and to identify the procedure most suitable for different types of herniations. Methods: Data were retrospectively collected from patients with L4-L5 disc herniation who underwent PETD or UBED between March 2018 and December 2019. Each group consisted of 34 consecutive patients. Key outcomes, including blood loss, operation time, fluoroscopic time, hospitalization duration, and herniation type, were analyzed and compared. Clinical efficacy was assessed using the Oswestry Disability Index (ODI), Visual Analog Scale (VAS), and modified MacNab criteria. Results: Significant differences were observed between the groups in terms of blood loss, operation time, and fluoroscopic time. Both groups demonstrated significant improvements in VAS scores for back and leg pain, as well as ODI. The proportion of patients achieving excellent or good outcomes was 88.2% for PETD and 91.2% for UBED. Notably, the PETD group had a higher proportion of intervertebral foramen-type disc herniations (32.4%) compared to the UBED group (2.9%; Conclusion: PETD is associated with less blood loss and shorter operation time, making it the preferred choice for intervertebral foramen-type herniations. UBED, with its shorter fluoroscopic time and reduced puncture difficulty, is more suitable for migration-type herniations. Both techniques are effective for treating central, axillary, and shoulder-type disc herniations. With proper patient selection, both PETD and UBED are safe and effective for L4-L5 disc herniation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.